Skip to main content

Compare Stocks

Date Range: 

 PolarityTEWindtree TherapeuticsEnzon PharmaceuticalsMicrobot MedicalIdera Pharmaceuticals
SymbolNASDAQ:PTENASDAQ:WINTOTCMKTS:ENZNNASDAQ:MBOTNASDAQ:IDRA
Price Information
Current Price$0.98$1.76$0.53$6.72$1.02
52 Week RangeBuyBuyN/ABuyHold
MarketRank™
Overall Score1.52.30.61.31.8
Analysis Score3.33.50.03.54.0
Community Score2.75.02.82.82.8
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.00.01.7
Earnings & Valuation Score1.31.30.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyN/ABuyHold
Consensus Price Target$3.00$12.25N/A$20.00$4.00
% Upside from Price Target207.16% upside596.02% upsideN/A197.62% upside292.16% upside
Trade Information
Market Cap$118.15 million$46.21 million$39.33 million$47.77 million$51.03 million
Beta1.290.250.773.982.4
Average Volume8,121,653460,019236,904145,7792,451,595
Sales & Book Value
Annual Revenue$5.65 million$200,000.00$210,000.00N/A$1.45 million
Price / Sales20.91231.06187.30N/A35.20
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.42 per share$5.48 per share$0.14 per share$5.02 per share($0.39) per share
Price / Book0.690.323.79N/A-2.62
Profitability
Net Income$-92,490,000.00$-27,480,000.00$-980,000.00$-7,250,000.00$-56,510,000.00
EPS($3.70)($2.52)N/AN/A($1.57)
Trailing P/E RatioN/AN/A0.000.00N/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-674.12%N/A-1,711.94%N/AN/A
Return on Equity (ROE)-169.92%-43.46%-20.29%-28.95%-771.38%
Return on Assets (ROA)-105.62%-26.55%-18.69%-26.60%-34.32%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.08%0.18%N/AN/AN/A
Current Ratio3.22%2.75%8.91%29.32%4.59%
Quick Ratio3.11%2.75%8.91%29.32%4.59%
Ownership Information
Institutional Ownership Percentage16.51%1.59%N/A9.47%25.05%
Insider Ownership Percentage5.50%14.91%0.03%8.69%3.50%
Miscellaneous
Employees8031N/A1432
Shares Outstanding120.97 million26.26 million74.22 million7.11 million50.03 million
Next Earnings Date8/5/2021 (Estimated)8/12/2021 (Estimated)5/20/2021 (Estimated)5/21/2021 (Estimated)8/3/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Contrasting Idera Pharmaceuticals (NASDAQ:IDRA) and ADMA Biologics (NASDAQ:ADMA)Contrasting Idera Pharmaceuticals (NASDAQ:IDRA) and ADMA Biologics (NASDAQ:ADMA)
americanbankingnews.com - May 14 at 2:10 AM
Zacks: Brokerages Anticipate Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) to Post -$0.20 EPSZacks: Brokerages Anticipate Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) to Post -$0.20 EPS
americanbankingnews.com - May 5 at 7:14 PM
Why should you add Idera Pharmaceuticals Inc. (IDRA) to your portfolio?Why should you add Idera Pharmaceuticals Inc. (IDRA) to your portfolio?
marketingsentinel.com - May 5 at 12:38 PM
What Do Wall Street Analysts Think About Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Stock?What Do Wall Street Analysts Think About Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Stock?
stocksregister.com - May 3 at 1:22 PM
Idera Pharmaceuticals (NASDAQ:IDRA) vs. Genetic Technologies (NASDAQ:GENE) Critical ReviewIdera Pharmaceuticals (NASDAQ:IDRA) vs. Genetic Technologies (NASDAQ:GENE) Critical Review
americanbankingnews.com - May 2 at 12:14 AM
Idera Pharmaceuticals (NASDAQ:IDRA) Posts Quarterly  Earnings Results, Beats Expectations By $0.08 EPSIdera Pharmaceuticals (NASDAQ:IDRA) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS
americanbankingnews.com - April 30 at 3:42 PM
Idera: Q1 Earnings Snapshot | Raleigh News & ObserverIdera: Q1 Earnings Snapshot | Raleigh News & Observer
newsobserver.com - April 29 at 6:07 PM
Idera: Q1 Earnings SnapshotIdera: Q1 Earnings Snapshot
timesunion.com - April 29 at 6:07 PM
Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate UpdateIdera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - April 29 at 6:07 PM
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Shares Look Bullish in 2021Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Shares Look Bullish in 2021
stocksregister.com - April 29 at 1:06 PM
Were Keeping An Eye On Idera Pharmaceuticals (NASDAQ:IDRA) Cash Burn RateWe're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
nasdaq.com - April 22 at 7:32 PM
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Given Average Recommendation of "Hold" by BrokeragesIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Given Average Recommendation of "Hold" by Brokerages
americanbankingnews.com - April 20 at 6:38 PM
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA): Why Investors Shouldn’t Ditch IDRA stock in 2021Idera Pharmaceuticals, Inc. (NASDAQ:IDRA): Why Investors Shouldn’t Ditch IDRA stock in 2021
marketingsentinel.com - April 20 at 2:07 PM
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Analysis: Is It The One You’re Looking For?Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Analysis: Is It The One You’re Looking For?
stocksregister.com - April 12 at 1:30 PM
Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) in 2021 Be Worth Your Money?Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) in 2021 Be Worth Your Money?
marketingsentinel.com - March 29 at 2:31 PM
Why Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Stock Might Be A Good InvestmentWhy Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Stock Might Be A Good Investment
stocksregister.com - March 26 at 3:14 PM
IDRA Stock Price Fell 62%: Why It HappenedIDRA Stock Price Fell 62%: Why It Happened
pulse2.com - March 22 at 7:49 AM
Thinking about buying stock in Skillz Inc, ZK International, Idera Pharmaceuticals, Upstart Holdings, or Plug Power?Thinking about buying stock in Skillz Inc, ZK International, Idera Pharmaceuticals, Upstart Holdings, or Plug Power?
prnewswire.com - March 19 at 1:04 PM
IDRA Stock Price Falls Over 60% Pre-Market: Why It HappenedIDRA Stock Price Falls Over 60% Pre-Market: Why It Happened
pulse2.com - March 19 at 1:04 PM
Why Idera Pharmaceuticals Stock Is Crashing TodayWhy Idera Pharmaceuticals Stock Is Crashing Today
finance.yahoo.com - March 19 at 1:04 PM
Latest Biotech Flop Shows Risks of Trading in Penny StocksLatest Biotech Flop Shows Risks of Trading in Penny Stocks
finance.yahoo.com - March 19 at 1:04 PM
Idera Pharmaceuticals stock plunges after disappointing trial results, prompting analyst downgradeIdera Pharmaceuticals stock plunges after disappointing trial results, prompting analyst downgrade
finance.yahoo.com - March 19 at 8:04 AM
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab ...Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab ...
apnews.com - March 19 at 3:03 AM
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced MelanomaIdera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma
finance.yahoo.com - March 19 at 3:03 AM
Are Options Traders Betting on a Big Move in Idera Pharmaceuticals (IDRA) Stock?Are Options Traders Betting on a Big Move in Idera Pharmaceuticals (IDRA) Stock?
finance.yahoo.com - March 18 at 1:04 PM
DateCompanyBrokerageAction
11/10/2020PolarityTECantor FitzgeraldReiterated Rating
9/8/2020PolarityTEOppenheimerReiterated Rating
7/24/2020PolarityTENorthland SecuritiesReiterated Rating
5/12/2020PolarityTEHC WainwrightReiterated Rating
11/13/2019PolarityTEPiper Jaffray CompaniesLower Price Target
5/13/2019PolarityTENational SecuritiesLower Price Target
6/26/2020Windtree TherapeuticsLADENBURG THALM/SH SHInitiated Coverage
3/25/2021Idera PharmaceuticalsJPMorgan Chase & Co.Reiterated Rating
3/25/2021Idera PharmaceuticalsJMP SecuritiesReiterated Rating
3/25/2021Idera PharmaceuticalsBarclaysReiterated Rating
3/25/2021Idera PharmaceuticalsWedbushReiterated Rating
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.